Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NIR Image-guided Resection for Lung Lesions
NCT03097575Phase 2Recruiting
- Sponsor
- Massachusetts General Hospital
- Start
- Jan 2015
- Primary completion
- Jan 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of indocyanine green in lung neoplasm, sponsored by Massachusetts General Hospital. Primary endpoint: Incidence of treatment-emergent adverse events at 5 years. Started Jan 2015; status: recruiting.
02
Drugs
indocyanine green
03
Conditions
lung neoplasm
Beyond the preview
Go deeper on NCT03097575.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03097575.